GCTK Stock — GlucoTrack Inc

GlucoTrack Inc (GCTK)

Updated October 16, 2026.

GCTK is a Stock. Total return is -100.0% over the past 13.5 years, 605.1 points behind SPY at 505.1%.

GlucoTrack, Inc. is a medical device company developing an implantable continuous blood glucose monitor for people with diabetes in the United States, primarily targeting Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to medical technology and diabetes management innovation rather than those focused on dividend income.

GCTK performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 13.5 years, 605.1 points behind SPY at 505.1%. Over the past year its total return — price change plus distributions reinvested — is -88.8%. Its deepest 1-year drawdown was 96.1%.

GCTK key facts

Asset type

Stock

Asset class

Equity

Inception date

04/25/2013

Distribution frequency

None

Last close

$0.72 (as of 2026-10-16)

Market cap

$738,062

Average volume

143683.0

Beta

0.726

Payout ratio

0.0%

EPS

$-123.15

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GCTK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 96.1%.

Who may consider GCTK — and who may not

It is a weaker fit for investors who need monthly cash flow (GCTK does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GCTK

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions